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Background. Anti-staphylococcal penicillins (ASPs) are recommended as first-line agents in methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Concerns about the safety profile have contributed to the increased use of cefazolin. The comparative clinical effectiveness and safety profile of cefazolin versus ASPs for such infections remain unclear.
Furthermore, uncertainty persists concerning the use of cefazolin due to controversies over its efficacy in deep MSSA infections and its possible negative ecological impact.
Aims. The aim of this narrative review was to gather and balance available data on the efficacy and safety of cefazolin versus ASPs in the treatment of MSSA bacteremia and to discuss the potential negative ecological impact of cefazolin.
Sources. PubMed and EMBASE electronic databases were searched up to May 2017 in order to retrieve available studies on the topic.
Contents.
While described in vitro and in experimental studies, the clinical relevance of the inoculum effect during cefazolin treatment of deep MSSA infections remains unclear. It appears that there is no significant difference in rate of relapse or mortality between ASPs and cefazolin for the treatment of MSSA bacteremia but these results should be cautiously interpreted because of the several limitations of the available studies. Compared to cefazolin, there is more frequent discontinuation for adverse effects with ASPs use, especially because of cutaneous and renal events. No study has evidenced any change in the gut microbiota after the use of cefazolin.
Implications. Based on currently available studies, there is no data allowing to choose one antibiotic over the other except in patients with allergy or renal impairment. This review points out the need for future prospective studies and randomized controlled trials to better address these questions.
Background
Methicillin-susceptible Staphylococcus aureus (S. aureus) (MSSA) bacteremia remains a major cause of community-or hospital-acquired bloodstream infections, with approximately 200,000 cases occurring annually in Europe [1] and high in-hospital mortality (25-35%) [2] [3] [4] . Anti-staphylococcal penicillins (ASPs) such as oxacillin or cloxacillin are recommended as first-line agents, but their use may be limited by concerns about their safety profile and difficult dosing schedule in patients with renal failure. Cefazolin, an intravenous firstgeneration cephalosporin, (1GC) is thus more and more used as an alternative option [5, 6] .
Yet the comparative clinical effectiveness and safety profile of cefazolin versus ASPs (nafcillin, oxacillin, cloxacillin, dicloxacillin or flucloxacillin) for MSSA infections remain unclear because of the limited published data. Furthermore, uncertainty persists for the curative use of cefazolin because of controversies concerning its efficacy in high-inoculum deep MSSA infections and its possible negative ecological impact.
Aims
The aim of this narrative review was to gather and balance available data on the efficacy and safety of cefazolin versus ASPs in the treatment of MSSA bacteremia and to discuss the potential negative ecological impact of cefazolin.
Sources
An extensive search of PubMed (January, 1985, to May, 2017) and EMBASE (January, 2010, to May, 2017) was performed to identify relevant studies for our review. Search terms included "cefazolin", "oxacillin", "nafcillin", "antistaphyloccocal penicillin", "methicillin", "β-lactams", "bacteremia", "bacteraemia", "bloodstream infection", "efficacy", "safety", "effectiveness", "inoculum effect", "gut microbiota", "resistances", "Staphylococcus aureus", Only studies published in English were considered in this review.
Content a. Inoculum effect
The inoculum effect has been defined as a significant rise in the cefazolin minimum inhibitory concentration (MIC) when the bacterial inoculum size is increased to 10 7 colony-forming units (CFU)/mL (instead of the standard 10 5 CFU/mL) [7] . Four different types (A, B, C and D) of staphylococcal β-lactamase enzymes have been characterized based on their substrate specificity and amino acid sequence [8] , and each of these has a different substrate profile [9] .
An inoculum effect of β-lactamase in MSSA has been suggested in vitro, with an MIC increase especially with blaZ type A β-lactamase. Type A β-lactamase efficiently hydrolyzes cefazolin [10] , but, not all isolates producing type A β-lactamase exhibit a significant cefazolin inoculum effect [11] [12] [13] [14] because of mechanisms that are not clearly known [15] .
However, a recent study has suggested that there might exist an association between type A blaZ gene polymorphism and cefazolin inoculum effect [16] .
In our review, the prevalence of β-lactamase ranges from 77 to 92% while Type A represents 15-34% and a cefazolin inoculum effect was found in 13 to 58% of the MSSA isolates. It seems that no significant association exists between inoculum effect positivity and demographic factors, underlying disease or site of infection [17] even though one study found that osteomyelitis is highly associated with cefazolin inoculum effect in South American hospitals [14] . Five studies assessed the clinical outcomes of the patients from whom MSSA isolates were collected depending on the presence of an inoculum effect. None found an impact of inoculum effect on mortality at day 90 and/or treatment failure. However, none of the studies was powered enough to evaluate the clinical impact of the cefazolin inoculum effect and the blaZ gene type. (Table 1) In vivo results are conflicting ( Table 2 ). Studies of MSSA infective endocarditis have shown that the in vitro inoculum effect may have consequences [18] [19] [20] , whereas other studies suggest that the slow inactivation of cefazolin by staphylococcal β-lactamase is of little importance, because diffusion into the area of infection occurs rapidly enough to yield effective antibacterial concentrations [21] .
In conclusion, the hydrolysis of cefazolin by S. aureus type A -lactamases in high-inoculum deep infections has been proven in vitro. However, its frequency in MSSA bacteremia has been found to be limited, ranging from 13 to 58% [12] [13] [14] 17, 22, 23] . The fact that it may lead to potential therapeutic failures is still debated with conflicting results in animal studies and six human studies that found no impact of the inoculum effect. However, these studies are limited by their small sample size, low rate of deep-seated infections and the presence of selection bias. Furthermore, the fact that neither susceptibility testing for cefazolin for MSSA nor the presence of type A -lactamases are routinely tested makes it difficult to gather data on the topic and to establish practical recommendations.
b. Clinical efficacy (Table 3)
Cloxacillin and cefazolin are more effective in the treatment of MSSA bacteremia than alternative treatments, with 2-fold and 3-fold increases in mortality rate with other β-lactams [24] and vancomycin [25] [26] [27] [28] [29] , respectively.
Although ASPs are the recommended treatment in MSSA bacteremia, the use of cefazolin in increasing. However, the quantity and quality of publishing data comparing clinical effectiveness of cefazolin versus ASPs are limited. So far, seven observational studies have compared cefazolin to ASPs in the treatment of MSSA bacteremia [24, [30] [31] [32] [33] [34] [35] . Six of these studies found no difference in treatment failure and/or mortality between cefazolin and ASPs groups with half of the studies reporting that cefazolin was associated with non-significant lower mortality [32] [33] [34] . Details on patients and infections characteristics, antibiotics dosing and duration, outcomes of interest and methods to control bias in the seven studies are displayed in Table 1 . 
c. Safety (Table 4)
Patients with MSSA infection often require prolonged administration of high-dose parenteral antimicrobial therapy with standard doses of 12 grams per day for oxacillin (25 to 50 mg/kg/4 to 6 hours) and 6 grams per day for cefazolin (25 to 50 mg/kg/8h). Because of aging and cumulating comorbidities in these patients, safety issues following the use of ASPs are not infrequent, especially hypersensitivity reactions (more than 10%) [36, 37] and renal impairment (more than 10%) [38] . Premature discontinuation of ASPs attributed to adverse events have been reported in 17 to 21% of treated patients for complicated MSSA bacteremia with standard doses of oxacillin or nafcillin (12g/24h) [30, 31] . In the case of chronic kidney disease with decreased glomerular filtration rate, ASP dosing is not clearly known.
Five studies have compared the occurrence of adverse events between cefazolin and ASPs among patients treated for MSSA bacteremia [30, 31, 33, 38, 39] . All but one study report higher adverse drug events in ASPs groups mainly due to nephrotoxicity and hypersensitivity reactions. These adverse drug events often required antibiotics discontinuation.
It appears that adverse event and criteria for discontinuation are not clearly defined across the studies with a wide range of nephrotoxicity definition for example. Furthermore, due to the retrospective nature of these studies, the quality of data collection is poor with important information biases. As for all observational studies, selection biases affect these safety studies. Severe patients, more likely to be concerned by acute renal failure or overdosing, are more frequently treated with ASPs.
d. Ecological impact on gut microbiota
In the current context of growing bacterial resistance, especially 3GC-resistant Enterobacteriaceae, the potential negative gut ecological impact of cephalosporins compared to very narrow spectrum antibiotics such as ASPs is largely debated. From a theoretical point of view, high biliary excretion of antibiotics and a sparing spectrum for anaerobes and lactobacilli may foster selection of high MIC Enterobacteriaceae, Clostridia and Candida by influencing the ecological balance of the gut microbiota. The biliary excretion of cefazolin is low and amounted to 0.03% of the administered dose, while 2-10% of a dose of cloxacillin or oxacillin can be recovered from bile [40] .
i. Ecological effect of ASPs on gut microbiota
Although, there are many studies of the effects of ASPs on skin flora, data on the ecological effects of ASPs on gut microbiota are scarce. Narrow spectrum penicillins seem to present a low risk for diarrhea associated with C. difficile in a systematic literature review published in 1998; ASPs seemed to present one of the lowest risks (OR 3.2; 95% CI 1.7-6.2), close to that of vancomycin (3.1; 95% CI 1.8-5.2), and much lower than broad spectrum antibiotics such as amoxicillin/clavulanic acid combination for example (22.1; 95% CI 6.5-75.4) [41] .
A Japanese study assessed the effect of antibiotics on the fecal flora in hospitalized children aged from 1 to 12 years, who received ampicillin (n=6), methicillin (n=8), cefpiramide (n=7) or ceftazidime (n=7). Antibiotic use was given for 5 to 14 days. Fifteen same aged hospitalized children who did not receive any antimicrobials served as controls. There was no significant decrease in the count of Enterobacteriaceae in patients treated with methicillin [42] .
ii. Ecological effect of C1G on gut microbiota
Ambrose et al. studied the influence of a single intravenous dose of antibiotic on gut microbiota and the emergence of C. difficile over two weeks in 78 volunteers (13 groups of 6 volunteers). Each group of 6 received either penicillins, from among benzyl penicillin, ampicillin, mezlocillin, piperacillin, ticarcillin, or cephalosporins, from among 1CG to 3CG, and the results were compared with those for a control group of 6 volunteers who received no antibiotic. Only cephalosporins were found to be associated with emergence of C. difficile, penicillins and controls were not. When they considered total aerobic counts, only the reduction after ceftriaxone achieved statistical significance (P<0.025) with decrease in counts of Escherichia coli, though an increase in the counts of enterococci was also observed in all groups. For the anaerobe count, only cefotetan was associated with a trend for decrease.
Overall, no significant changes were observed for cefazolin [43] .
Knothe et al. investigated in healthy volunteers the effects on gut microbiota of 1GC
(cefazolin) and 3CG (cefotaxime). One or two stool specimens were taken before, during and several days after medication. No selection of strains resistant to ampicillin or cefazolin occurred, while cefazolin considerably reduced Bacteroides spp., lactobacilli and
Enterobacteriaceae [44] . While, the negative ecological impact of cephalosporin use is known, few clinical studies specifically assessed the impact of 1GC on gut microbiota [43] [44] [45] . Indeed, despite its wide use in antimicrobial prophylaxis in surgical care, no study has clearly assessed the ecological impact of cefazolin. In the reviewed studies, no change in counts of Enterobacteriaceae, enterococci, yeasts, total anaerobes, Clostridia spp. or Bacteroides spp. was observed after administration of cefaloridine, cefalotine or cefazolin. However, it seems that significant changes begin from second cephalosporin generations use [43] .
In the current era of growing antimicrobial resistance, the ecological impact has to be considered among potential adverse effects of antibiotics, especially when one has to balance between penicillin and cephalosporin. 
Implications
The quality of the published data comparing ASPs and cefazolin as treatment options for MSSA bacteremia is insufficient while the associated morbidity and mortality are high in this frequent disease. While described in vitro and in experimental studies, the clinical relevance of the inoculum effect during cefazolin treatment of deep MSSA infections remains uncertain.
This inoculum effect which appears to be infrequent, is not routinely tested in microbiological labs making its impact difficult to assess in routine care.
From a clinical point of view, it seems that there is no difference in efficacy between these drugs. However, available data on clinical efficacy are from retrospective studies that are affected by selection biases issue. Despite concerns about the possible negative ecological impact of cefazolin, no studies have evidenced changes in gut microbiota after its use, but the designs of the available studies are all too old to be able to correctly assess this issue.
Concerning safety, it appears that adverse events, especially cutaneous and renal, are more frequent with ASPs than with cefazolin. All these points need to be confirmed in randomized controlled trials that should take into account ecological data.
Based on these reviewed data and our clinical experience, we suggest using cefazolin in catheter related infections, skin/soft tissue infection, non-complicated IE and bone and joint infection because of the excellent bone penetration [46, 47] . Conversely, because of the poor penetration of cefazolin through the blood-brain barrier [48, 49] , ASPs should be preferred for central nervous system infections. In case of complicated IE and deep-seated abscesses, because of the hypothetical risk of clinical failure due to the inoculum effect, ASPs should rather be considered along with source control when possible. In case of deep-seated infection and complete stock-out of ASPs, source control and an increase in cefazolin dosing (>6g/day) should help mitigating the inoculum effect.
Competing interests.
The authors declare no commercial or other association that might pose a conflict of interest.
Funding statement.
The current work received no funds. 
